XML 53 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Agreement with Eli Lilly and Company - Other (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Nov. 02, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
item
Sep. 30, 2018
USD ($)
Collaborative Arrangements        
Equity investment       $ 31,000
Revenue   $ 1,583 $ 4,342  
Lilly Agreement        
Collaborative Arrangements        
Period of expiry from date of agreement 4 years      
Upfront non-refundable payment received $ 25,000      
Equity investment 15,000      
The number of performance obligations. | item     2  
Revenue   $ 1,600 $ 4,300  
Lilly Agreement | Lilly        
Collaborative Arrangements        
Maximum development and regulatory milestones and sales milestone receivable 1,400,000      
Maximum development and regulatory milestones and sales milestone payable upon option exercise 710,000      
Transaction price $ 32,700